🇺🇸 FDA
Pipeline program

TREPaed_10, TREPaed_5, TREPaed_0.5, TREPaed_2.5, TREPaed_1

TREPaed

Phase 3 small_molecule active

Quick answer

TREPaed_10, TREPaed_5, TREPaed_0.5, TREPaed_2.5, TREPaed_1 for Pulmonary Arterial Hypertension (PAH) is a Phase 3 program (small_molecule) at AOP Orphan Pharmaceuticals GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
AOP Orphan Pharmaceuticals GmbH
Indication
Pulmonary Arterial Hypertension (PAH)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials